Eli Lilly (LLY) Offering Possible 6.38% Return Over the Next 7 Calendar Days

Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $112.00 short put and a strike $107.00 long put offers a potential 6.38% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $112.00 by expiration. The full premium credit of $0.30 would be kept by the premium seller. The risk of $4.70 would be incurred if the stock dropped below the $107.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 77.98 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Eli Lilly

Here’s why you should expect more ‘beats’ during this earnings season
Thu, 11 Oct 2018 02:55:00 +0000
It’s common for earnings ‘beats’ to be set up by companies by lowering expectations. But analysts have raised price targets for many companies too.

The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares
Wed, 10 Oct 2018 11:56:57 +0000
Here’s a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 9) BioDelivery Sciences International, Inc. (NASDAQ: BDSI …

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
Wed, 10 Oct 2018 10:30:00 +0000
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 10, 2018 /PRNewswire/ — Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that treatment with Jardiance® positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease, Boehringer Ingelheim and Eli Lilly and Company (LLY) announced today. Using actuarial methods*, and assuming that the demonstrated beneficial effects of Jardiance remain consistent with long-term use, Jardiance was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo. This analysis suggests that treatment with Jardiance could add years of life.

Lilly’s Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
Tue, 09 Oct 2018 21:02:00 +0000
Lilly’s Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

4 Reasons to Be Wary of This Animal Health IPO
Tue, 09 Oct 2018 20:11:00 +0000
Eli Lilly’s spin-off of Elanco creates a new investment opportunity in a growing market, but should you jump in?

Be Sociable, Share!

Related Posts